Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates

  • ACS Med Chem Lett. 2018 Jun 6;9(7):757-760. doi: 10.1021/acsmedchemlett.8b00213.
Sean P Brown  1 ,  Paul Dransfield  1 ,  Marc Vimolratana  1 ,  Liusheng Zhu  1 ,  Jian Luo  1 ,  Jane Zhang  1 ,  XianYun Jiao  1 ,  Vatee Pattaropong  1 ,  Simon Wong  1 ,  Run Zhuang  1 ,  Gayathri Swaminath  1 ,  Jonathan B Houze  1 ,  Daniel C-H Lin  1
Affiliations
  • 1. Department of Medicinal Chemistry, Amgen Discovery Research, One Amgen Center Drive, Thousand Oaks, California 91320, United States.
Abstract

GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets and enteroendocrine L-cells, and, when activated, elicits increased Insulin secretion only in the presence of elevated glucose levels. We recently reported the discovery of AM-1638 (2), a full agonist of GPR40. Herein, we present further structure-activity relationships progressing from AM-1638 (2) to AM-6226 (14) that possesses a profile acceptable for dosing cynomolgus monkeys. The GPR40 full agonist AM-6226 (14) is the first molecule to display significant glucose lowering in cynomolgus monkeys providing additional evidence that GPR40 full agonists afford access to a powerful mechanism for maintaining glycemic control.

Products